PHRRF Pharmather Holdings Ltd

$PHRRF This is a good step forward: Strategic Assets Its FDA-approved ketamine ANDA, sale US$25 million over time, subject to commercial performance, with payments expected to begin in Q1 2027. Upcoming Milestones Q4 2026: initial CraftMake™ orders; first proprietary 503A product launches; initial white-label and CDMO agreements; orphan drug and rare pediatric disease designation applications. Q1 2027: ketamine dissolvable tablet launch for telehealth; first ketamine ANDA payments expected; pre-IND meeting with the FDA on the rare pediatric program. Next 12 months: up to 50 CraftMake™ placements; telehealth partnerships and further white-label and CDMO agreements; national emergency demonstration. 2027–2028: M3DICINES™ formulation licences; government readiness contracts; an expanded product portfolio, including ultra-rare disease, psychedelic Q4 2028: rare pediatric NDA submission (target). $CLGN $DDD $SSYS

$PHRRF Dear Management, Enough of the partnership, agreements news. Its high time you publish - how much of those $25 million profit sharing payments achieved ? Only those numbers put it at $1 and above.

$PHRRF When are they going to update the Financials on Ketamine ANDA Sale Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments?

$PHRRF - Confirmed triggered multiple intersept price in changing mode - Foundation technical clouds - break out

$PHRRF - Recent Corporate UpdatesPersonalized Medicine Expansion: PharmaTher established PERSONALIZ3D in August 2026 to commercialize a personalized medicine platform combining telehealth and pharmaceutical 3D printing, selecting PD Labs as its U.S. Center of Excellence

$PHRRF - Chart looks like an execution? Volume demand, Bullish, Possible swing and breakout outlook?